Abstract
Novartis AG will report its latest quarterly results on October 27, 2026, Pre-MKt; this preview compiles the latest financial metrics, consensus forecasts, and institutional commentary to frame expectations for revenue, margins, net income, and adjusted EPS alongside the company’s near-term operational dynamics.Market Forecast
Consensus points to steady top-line and earnings progression this quarter, with Novartis AG’s revenue projected at 14.47 billion US dollars, up 4.00% year over year, EBIT estimated at 5.48 billion US dollars with 2.97% YoY growth, and adjusted EPS estimated at 2.29, implying 2.73% YoY growth; margin forecasts have not been formally provided. The company’s main commercial portfolio is expected to show balanced momentum, with stronger prescription trends in certain newer therapies offsetting loss-of-exclusivity pressure in selected cardiovascular assets and a mild foreign-exchange headwind into the print. The most promising near-term growth area remains the neuroscience and immunology franchise anchored by multiple sclerosis therapies, with last quarter segment revenue of 1.88 billion US dollars; analysts expect continued YoY growth in this area this quarter driven by prescription strength and pipeline catalysts.Last Quarter Review
Novartis AG delivered last quarter revenue of 14.41 billion US dollars (up 2.52% YoY), a gross profit margin of 75.40%, GAAP net profit attributable to shareholders of 3.26 billion US dollars with a net profit margin of 21.83%, and adjusted EPS of 2.41 (down 0.41% YoY). A notable financial highlight was EBIT of 5.94 billion US dollars, which exceeded the prior consensus by approximately 0.54 billion US dollars while registering a slight YoY increase. On the commercial side, Oncology contributed 4.52 billion US dollars, Immunology generated 2.78 billion US dollars, Neuroscience reached 1.88 billion US dollars, and Cardiovascular, Renal and Metabolism delivered 1.69 billion US dollars as total group revenue expanded 2.52% year over year.Current Quarter Outlook
Main Commercial Portfolio
The core portfolio is expected to post modestly positive growth in the current quarter, with total revenue estimated at 14.47 billion US dollars, implying a 4.00% year-over-year increase. The revenue mix suggests Oncology and Immunology should continue to anchor absolute top-line contribution while Neuroscience adds incremental acceleration, based on observed prescription momentum reported by analysts. The previous quarter’s gross profit margin of 75.40% and net profit margin of 21.83% set a high-quality baseline entering this quarter, though the company has not issued a formal margin forecast for the period.Within the cardiovascular and metabolic franchise, headwinds from the loss of exclusivity on certain therapies are expected to persist in the quarter. Analysts flag ongoing erosion for a key heart-failure therapy, with one brokerage estimating about 1.12 billion US dollars in quarterly revenue for that asset and a sharp year-over-year decline in prescriptions. This pressure is likely to be offset by stronger trajectories in newer products, underpinning the stable-to-growing EBIT outlook; consensus for EBIT stands at 5.48 billion US dollars, a 2.97% YoY increase.
Currency remains a consideration. Analysts anticipate approximately a 0.50% headwind to the revenue line from foreign exchange in the quarter. Operational execution across launches and disciplined cost control should help protect earnings despite this FX drag and the cardiovascular LOE impact. The net result implied by consensus is a balanced quarter with adjusted EPS projected at 2.29, up 2.73% year over year.
Neuroscience and Immunology Growth Engines
Neuroscience and Immunology are positioned to deliver the most visible growth contributions this quarter. Neuroscience revenue was 1.88 billion US dollars last quarter, and prescription-trend commentary from analysts suggests continued growth in the multiple sclerosis franchise this quarter. The segment’s growth focus includes both the marketed portfolio and late-stage pipeline, with catalysts around data updates for next-generation therapies.A late-stage multiple sclerosis program has featured prominently in recent investor updates, contributing to higher confidence in medium-term trajectory. The news flow over the past two months has included successful late-stage trial signals for an oral therapy in relapsing MS and regulatory progress for immunology indications, which together support the expectation of ongoing adoption. These developments, alongside continued commercial execution, underpin the consensus EPS trajectory.
Immunology held at 2.78 billion US dollars last quarter and should benefit from label expansions and broader geographic uptake. A recent regulatory expansion in the United States for a chronic skin disease therapy adds a potential incremental driver. Management’s disciplined allocation to late-stage assets and external innovation—highlighted by a licensing and option agreement to develop RNA-encoded therapeutics with sizeable milestone potential—broadens the optionality set for the franchise into autoimmune indications. While the revenue impact from such partnerships is longer-dated and contingent on development milestones, near-term sentiment may benefit from the strategic scope and scientific validation they provide.
Stock-Price Sensitivity Factors This Quarter
Trial outcomes and pipeline updates remain a key determinant of share-price volatility into and around the result date. Recent negative readouts, including a Phase 3 failure in a genetic muscle disorder and the pelacarsen outcome, prompted premarket share moves, underscoring the market’s sensitivity to binary events even when guidance remains unchanged. Conversely, positive late-stage signals in MS and regulatory expansions in immunology have supported the shares, reinforcing the asymmetric impact of news flow during the earnings window.Commercial durability and guidance confidence will be closely watched. Analysts indicate that management remains aligned with a second-half revenue and core operating income framework, helping to anchor expectations around the mid-single-digit revenue growth range implied by consensus for the quarter. Commentary on execution in Oncology and Neuroscience, together with clarity on cardiovascular erosion dynamics, will likely shape the market’s view of the sustainability of the EBIT and EPS trajectory into year-end.
Foreign exchange and capital deployment add further context. One brokerage estimates a roughly 0.50% FX headwind to the top line this quarter, which could modestly temper reported revenue growth. Investors will also monitor any commentary related to prior acquisitions and external innovation partnerships; shareholder feedback has emphasized oversight and discipline following recent portfolio and M&A developments. As such, guidance color and capital-allocation signals may drive post-report price reaction alongside core operating metrics.
Analyst Opinions
Bullish views predominate in the latest six-month window, with a clear tilt toward constructive expectations into the print. Based on the collected opinions, bullish vs bearish stands at 2:0 among clearly directional calls, with supportive views citing prescription momentum in Neuroscience and Oncology, stable execution through currency and LOE headwinds, and a credible path to mid-single-digit revenue growth and incremental margin sustainment. One well-known independent research house reaffirmed a Buy rating with a 160.00 US dollars target, highlighting steady execution and a visible product-cycle underpinning for near-term EPS. A thematic note from a healthcare research boutique expressed a near-term preference for Novartis AG within a basket of European pharma names, referencing forthcoming strategy updates and potential AI-enabled productivity gains as ancillary supports.The minority neutral stance centers on balanced risk-reward into October 27, 2026, highlighting two counterweights: a continuing revenue drag from loss of exclusivity in cardiovascular and modest FX pressure of about 0.50% on the quarter’s top line. That same neutral analysis nevertheless aligns with the company’s second-half revenue and core operating income framework, citing stronger prescriptions for the multiple sclerosis therapy and a chronic myeloid leukemia therapy as offsets to cardiovascular erosion. Importantly, it identifies a key near-term catalyst in relapsing MS data, which could recalibrate the market’s multiple if outcomes are favorable.
In aggregate, the majority of analysts emphasize that the commercial engine has enough breadth to absorb LOE headwinds while still delivering moderate growth in revenue, EBIT, and adjusted EPS this quarter. On balance, the constructive camp frames the print as a test of consistency: modest top-line expansion, upheld operating discipline, and reassurance on the cadence of launches and late-stage milestones. If management affirms trajectory and contextualizes recent pipeline outcomes within a durable plan, bulls expect the narrative to remain anchored to incremental growth and disciplined capital allocation through year-end.
Comments